Legend Biotech to Participate in the 41st Annual JP Morgan Healthcare Conference

Jan 04, 2023

SOMERSET, N.J.—January 3, 2023—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced its participation in the 41st annual JP Morgan Healthcare Conference in San Francisco, CA.

CEO Ying Huang, Ph.D. will deliver the company presentation on Tuesday, January 10, 2023 at 2:15 pm (Pacific Time).


About Legend Biotech 

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.  

Learn more at www.legendbiotech.com and follow us on Twitter and LinkedIn.   

Investor Contacts:  

Joanne Choi, Senior Manager, Investor Relations, Legend Biotech 


Crystal Chen, Manager, Investor Relations, Legend Biotech  


Press Contact:  

Tina Carter, Corporate Communications Lead, Legend Biotech  


(908) 331-5025  


You are about to leave LegendBiotech.com

You are going to a website that Legend Biotech does not operate and to which Legend Biotech's privacy policy does not apply. Legend Biotech is not responsible for the content, format, maintenance or policies of the website you are about to visit and does not endorse or monitor any content on such website.

We use cookies to improve your experience on our website, measure performance, understand our audience, for advertising and support purposes. You can always change your preferences or opt out from our use of cookies.